September 13, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: | Justin Dobbie |
Julia Griffith
Sharon Blume
Christine Torney
Re: | IGM Biosciences, Inc. |
Registration Statement on Form S-1
File No. 333-233365
Acceleration Request
Requested Date: Tuesday, September 17, 2019
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, IGM Biosciences, Inc. (the Company) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-233365) (the Registration Statement) be declared effective at the Requested Date and Requested Time set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Jennifer Knapp at (650) 849-3041.
[Signature page follows]
Securities and Exchange Commission
September 13, 2019
Page 2
Sincerely, |
IGM BIOSCIENCES, INC. |
/s/ Fred Schwarzer |
Fred Schwarzer |
Chief Executive Officer and President |
cc: | Misbah Tahir, IGM Biosciences, Inc. |
Paul Graffagnino, GCA Law Partners LLP
Tony Jeffries, Wilson Sonsini Goodrich & Rosati, P.C.
Kenneth A. Clark, Wilson Sonsini Goodrich & Rosati, P.C.
Jennifer Knapp, Wilson Sonsini Goodrich & Rosati, P.C.
Jonie I. Kondracki, Cooley LLP
Charles S. Kim, Cooley LLP
September 13, 2019
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, N.E.
Washington, DC 20549
Attention: | Justin Dobbie |
Julia Griffith
Sharon Blume
Christine Torney
Re: | IGM Biosciences, Inc. |
Registration Statement on Form S-1 (File No. 333-233365)
Ladies and Gentlemen:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that between September 3, 2019 and the date hereof, approximately 1,140 copies of the Preliminary Prospectus dated September 3, 2019 were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement.
We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on Tuesday, September 17, 2019 or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
JEFFERIES LLC
PIPER JAFFRAY & CO.
STIFEL, NICOLAUS & COMPANY, INCORPORATED
As representatives of the Underwriters
By: | Jefferies LLC |
By: | /s/ Dustin Tyner | |||
Name: | Dustin Tyner | |||
Title: | Managing Director |
By: |
Piper Jaffray & Co. |
By: |
/s/ Chris Collins | |||
Name: |
Chris Collins | |||
Title: |
Managing Director |
By: |
Stifel, Nicolaus & Company, Incorporated |
By: |
/s/ Nathan Thompson | |||
Name: |
Nathan Thompson | |||
Title: |
Director |
[IGM Biosciences, Inc. Signature Page to the Acceleration Request]